MAB4133
Anti-p16 Antibody, clone D25
clone D25, Chemicon®, from mouse
Synonym(s):
INK4a, MTS1, CDK4IN, CDKN2
Sign Into View Organizational & Contract Pricing
All Photos(2)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Pricing and availability is not currently available.
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
D25, monoclonal
species reactivity
human
manufacturer/tradename
Chemicon®
technique(s)
immunohistochemistry: suitable
western blot: suitable
isotype
IgG1
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... CDKN2A(1029)
Specificity
P16* is a major tumor suppressor gene, which is known to be deleted or mutated in many types of human cancers. Antibody MAB4133 binds specifically to p16 in its recombinant or native form. It also recognizes p16 expressed by melanomas and neve in situ.
Immunogen
Recombinant p16 fusion protein from E. coli.
Application
Anti-p16 Antibody, clone D25 is a Mouse Monoclonal Antibody for detection of p16 also known as INK4a, MTS1, CDK4IN, CDKN2 & has been validated in WB & IHC.
Immunoblotting
Immunohistochemistry
Optimal working dilutions must be determined by end user.
Immunohistochemistry
Optimal working dilutions must be determined by end user.
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Cell Cycle, DNA Replication & Repair
Cell Cycle, DNA Replication & Repair
Linkage
Replaces: 04-239
Physical form
Format: Purified
Liquid in phosphate buffer, containing azide as a preservative.
Storage and Stability
Maintain refrigerated at 2-8°C in undiluted aliquots for up to 12 months.
Analysis Note
Control
POSITIVE CONTROL: HeLa cells
colon carcinoma
POSITIVE CONTROL: HeLa cells
colon carcinoma
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
10 - Combustible liquids
WGK
WGK 2
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
N Zhao et al.
British journal of cancer, 107(3), 482-490 (2012-06-28)
Recently, the management of head and neck squamous cell carcinoma (HNSCC) has focused considerable attention on biomarkers, which may influence outcomes. Tests for human papilloma infection, including direct assessment of the virus as well as an associated tumour suppressor gene
Matt Lechner et al.
Oral oncology, 83, 32-37 (2018-08-14)
p16INK4A (p16) is the most widely used clinical biomarker for Human Papillomavirus (HPV) in head and neck squamous cell cancer (HNSCC). HPV is a favourable prognostic marker in HNSCC and is used for patient stratification. While p16 is a relatively
Alhadi Almangush et al.
British journal of cancer, 117(6), 856-866 (2017-07-29)
Identifying informative prognostic biomarkers for oral tongue squamous cell carcinoma (OTSCC) is of great importance in order to better predict tumour behaviour and to guide treatment planning. Here, we summarise existing evidence regarding immunohistochemical prognostic biomarkers for OTSCC. A systematic
Amelia B Thompson et al.
Journal of lower genital tract disease, 22(4), 340-347 (2018-09-01)
Anal cancer rates are increasing among HIV-infected persons. Although an efficacious human papillomavirus (HPV) vaccine is available, HPV vaccination rates remain low. Therefore, providers perform anal cancer screening, but there is no consensus on the optimal methods or timing of
C Grønhøj Larsen et al.
British journal of cancer, 110(6), 1587-1594 (2014-02-13)
A significant proportion of squamous cell carcinomas of the oropharynx (OP-SCC) are related to human papillomavirus (HPV) infection and p16 overexpression. This subgroup proves better prognosis and survival but no evidence exists on the correlation between HPV and p16 overexpression
Active Filters
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service
